The intravenous to oral switch of taxanes: strategies and current clinical developments

Papers of special note have been highlighted as: •• of considerable interest

References

• 1. Gotwals P, Cameron S, Cipolletta D et al. Prospects for combining targeted and conventional therapy with immunotherapy. Nat. Rev. Cancer 17(5), 286–301 (2017).
  Medline CASGoogle Scholar
• 2. Archer VR, Billingham LJ, Cullen MH. Palliative chemotherapy: no longer a contradiction in terms. Oncologist 4(6), 470–477 (1999).
  Medline CASGoogle Scholar
• 3. Liu G, Franssen E, Fitch MI, Warner E. Patient preference for oral versus intravenous palliative chemotherapy. J. Clin. Oncol. 15(1), 110–115 (1997).
  Medline CASGoogle Scholar
• 4. Borner M, Scheithauer W, Twelves C, Maroun J, Wilke H. Answering patient's needs: oral alternatives to intravenous therapy. Oncologist 6(Suppl. 4), 12–16 (2001).
  MedlineGoogle Scholar
• 5. Le Lay K, Myon E, Hill S et al. Comparative cost-minimisation of oral and intravenous chemotherapy for first-line treatment of non-small cell lung cancer in the UK NHS system. Eur. J. Health Econ. 8(2), 145–151 (2007).
  MedlineGoogle Scholar
• 6. Cassidy J, Douillard JY, Twelves C et al. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes C colon cancer: the X-ACT trial. Br. J. Cancer 94(8), 1122–1129 (2006).
  Medline CASGoogle Scholar
• 7. van de Haar J, Hoes LR, Coles CE et al. Caring for patients with cancer in the COVID-19 area. Nat. Med. 26, 665–671 (2020).
  MedlineGoogle Scholar
• 8. Meerum Terwogt JM, Schellens JHM, ten Bokkel Huinink WW, Beijnen JH. Clinical pharmacology of anticancer agents in relation to formulations and administration routes. Cancer Treat. Rev. 25(2), 83–101 (1999).
  MedlineGoogle Scholar
• 9. Seidman AD, Berry D, Cirrincione C et al. Randomized Phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J. Clin. Oncol. 26(10), 1642–1649 (2008).
  Medline CASGoogle Scholar
• 10. Bocci G, Di Paolo A, Danesi R. The pharmacological bases of antiangiogenic activity of paclitaxel. Angiogenesis 16, 481–492 (2013).
  Medline CASGoogle Scholar
• 11. Hennenfent KL, Govindan R. Novel formulations of taxanes: a review. Old wine in a new bottle? Ann. Oncol. 17(5), 735–749 (2006).
  Medline CASGoogle Scholar
• 12. Banna GL, Collovà E, Gebbia V et al. Anticancer oral therapy: emerging related issues. Cancer Treat. Rev. 36(8), 595–605 (2010). •• Describes the advantages and challenges of oral anticancer treatment.
  MedlineGoogle Scholar
• 13. O'Neill VJ, Twelves CJ. Oral cancer treatment: developments in chemotherapy and beyond. Br. J. Cancer 87(9), 933–937 (2002).
  MedlineGoogle Scholar
• 14. Jacobs JM, Ream ME, Pensak N et al. Patient experiences with oral chemotherapy: adherence, symptoms and quality of life. J. Natl Compr. Canc. Netw. 17(3), 221–228 (2019).
  MedlineGoogle Scholar
• 15. Sohail MF, Rehman M, Sarwar SH et al. Advancements in the oral delivery of docetaxel: challenges, current state-of-the-art and future trends. Int. J. Nanomedicine 13, 3145–3161 (2018).
  Medline CASGoogle Scholar
• 16. Flores JP, Saif MW. Novel oral taxane therapies: recent Phase I results. Clin. Investig. (Lond.) 3(4), 333–341 (2013).
  Medline CASGoogle Scholar
• 17. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. 93, 2325–2327 (1971).
  Medline CASGoogle Scholar
• 18. Slichenmeyer WJ, von Hoff DD. Taxol: a new and effective anti-cancer drug. Anticancer Drugs 2(6), 519–530 (1991).
  MedlineGoogle Scholar
• 19. Thigpen T, Vance R, Puneky L, Khansur T. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials. Gynecol. Oncol. 55(3 Pt 2), S97–S107 (1994).
  Medline CASGoogle Scholar
• 20. Ozols RF. Paclitaxel (taxol)/carboplatin combination therapy in the treatment of advanced ovarian cancer. Semin. Oncol. 27(3 Suppl. 7), 3–7 (2000).
  Medline CASGoogle Scholar
• 21. Seidman AD. The emerging role of paclitaxel in breast cancer therapy. Clin. Cancer Res. 1(3), 247–256 (1995).
  Medline CASGoogle Scholar
• 22. Piccart-Gebhart MJ, Burzykowski T, Buyse M et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J. Clin. Oncol. 26(12), 1980–1986 (2008).
  Medline CASGoogle Scholar
• 23. Gligorov J, Richard S. Breast cancer: weekly paclitaxel – still preferred first-line taxane for mBC. Nat. Rev. Clin. Oncol. 12(9), 508–509 (2015).
  Medline CASGoogle Scholar
• 24. Peto R, Davies C, Godwin J et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analysis of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379(9814), 432–444 (2012).
  Medline CASGoogle Scholar
• 25. Tolaney SM, Barry WT, Dang CT et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N. Engl. J. Med. 372(2), 134–141 (2015).
  MedlineGoogle Scholar
• 26. Giaccone G, Splinter TA, Debruyne C et al. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J. Clin. Oncol. 16(6), 2133–2141 (1998).
  Medline CASGoogle Scholar
• 27. Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature 533(7689), 446–454 (2018).
  Google Scholar
• 28. Vanni T, Sprinz E, Machado MW, Santana Rde C, Fonseca BA, Schwartsmann G. Systemic treatment of AIDS-related Kaposi sarcoma: current status and perspectives. Cancer Treat. Rev. 32(6), 445–455 (2006).
  Medline CASGoogle Scholar
• 29. Tulpule A, Groopman J, Saville MW et al. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma. Cancer 95(1), 147–154 (2002).
  Medline CASGoogle Scholar
• 30. Sakamoto J, Matsui T, Kodera Y. Paclitaxel chemotherapy for the treatment of gastric cancer. Gastric Cancer 12, 69–78 (2009).
  Medline CASGoogle Scholar
• 31. Wilke H, Muro K, van Cutsem E et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised Phase 3 trial. Lancet Oncol. 15(11), 1224–1235 (2014).
  Medline CASGoogle Scholar
• 32. Muro K, van Cutsem E, Narita Y et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann. Oncol. 30(1), 19–33 (2019).
  Medline CASGoogle Scholar
• 33. Denis JN, Greene AE, Guénard D, Guerritte-Voegelein F, Mangatal L, Potier P. A highly efficient, practical approach to natural taxol. J. Am. Chem. Soc. 110(17), 5917–5919 (1988).
  CASGoogle Scholar
• 34. Pronk LC, Stoter G, Verweij J. Docetaxel (taxotere): single agent activity, development of combination treatment and reducing side effects. Cancer Treat. Rev. 21(5), 463–478 (1995).
  Medline CASGoogle Scholar
• 35. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351(15), 1502–1512 (2014).
  Google Scholar
• 36. Sathianathen NJ, Philippou YA, Kuntz GM et al. Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer. Cochrane Database Syst. Rev. 10, CD012816 (2018).
  MedlineGoogle Scholar
• 37. Nabholtz JM, Senn HJ, Bezwoda WR et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J. Clin. Oncol. 17(5), 1413–1424 (1999).
  Medline CASGoogle Scholar
• 38. Sjöström J, Blomqvist C, Mouridsen H et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised Phase III study with crossover on progression by the Scandinavian Breast Group. Eur. J. Cancer 35(8), 1194–1201 (1999).
  Medline CASGoogle Scholar
• 39. O'Shaughnessy J, Miles D, Vukelja S et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J. Clin. Oncol. 20(12), 2812–2823 (2002).
  MedlineGoogle Scholar
• 40. Swain SM, Kim SB, Cortes J et al. Pertuzumab, trastuzumab and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomized, double-blind, placebo-controlled, Phase 3 study. Lancet Oncol. 14(6), 461–471 (2013).
  Medline CASGoogle Scholar
• 41. Mackey JR, Martin M, Pienkowski T et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the Phase 3 randomised BCIRG 001 trial. Lancet Oncol. 14(1), 72–80 (2013).
  Medline CASGoogle Scholar
• 42. Willson ML, Burke L, Ferguson T, Ghersi D, Nowak AK, Wilcken N. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst. Rev. 9, CD004421 (2019).
  MedlineGoogle Scholar
• 43. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 18(10), 2095–2103 (2000).
  Medline CASGoogle Scholar
• 44. Fossella FV, DeVore R, Kerr RN et al. Randomized Phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J. Clin. Oncol. 18(12), 2354–2362 (2000).
  Medline CASGoogle Scholar
• 45. Vokes EE, Ready N, Felip E et al. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann. Oncol. 29(4), 959–965 (2018).
  Medline CASGoogle Scholar
• 46. Caponigro F, Longo F, Perri F, Ionna F. Docetaxel in the management of head and neck cancer. Anticancer Drugs 20(8), 639–645 (2009).
  Medline CASGoogle Scholar
• 47. Lorch JH, Goloubeva O, Haddad RI et al. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised Phase 3 trial. Lancet Oncol. 12(2), 153–159 (2011).
  Medline CASGoogle Scholar
• 48. Thuss-Patience PC, Kretzschmar A, Reichardt P. Docetaxel in the treatment of gastric cancer. Future Oncol. 2(5), 603–620 (2006).
  CASGoogle Scholar
• 49. Cutsem E, Moiseyenko VM, Tjulandin S et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J. Clin. Oncol. 24(31), 4991–4997 (2006).
  MedlineGoogle Scholar
• 50. Wagner AD, Syn NL, Moehler M et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst. Rev. 8, CD004064 (2017).
  MedlineGoogle Scholar
• 51. Mita AC, Figlin R, Mita MM. Cabazitaxel: more than a new taxane for metastatic castrate-resistant prostate cancer? Clin. Cancer Res. 18(24), 6574–6579 (2012).
  Medline CASGoogle Scholar
• 52. De Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376(9747), 1147–1154 (2010).
  MedlineGoogle Scholar
• 53. Oudard S, Fizazi K, Sengeløv L et al. Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized Phase III trial – FIRSTANA. J. Clin. Oncol. 35(28), 3189–3197 (2017).
  Medline CASGoogle Scholar
• 54. Eisenberger M, Hardy-Bessard AC, Kim CS et al. Phase III study comparing a reduced dose of cabazitaxel (20 mg/m²) and the currently approved dose (25 mg/m²) in postdocetaxel patients with metastatic castration-resistant prostate cancer – PROSELICA. J. Clin. Oncol. 35(28), 3198–3206 (2017).
  Medline CASGoogle Scholar
• 55. Pivot X, Koralewski P, Hidalgo JL et al. A multicenter Phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann. Oncol. 19(9), 1547–1552 (2008).
  Medline CASGoogle Scholar
• 56. Villanueva C, Awada A, Campone M et al. A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a Phase I/II study. Eur. J. Cancer 47(7), 1037–1045 (2011).
  Medline CASGoogle Scholar
• 57. Hendrikx JJMA, Lagas JS, Rosing H, Schellens JHM, Beijnen JH, Schinkel AH. P-glycoprotein and cytochrome P450 3A4 act together in restricting the oral bioavailability of paclitaxel. Int. J. Cancer 132(10), 2439–2447 (2013).
  Medline CASGoogle Scholar
• 58. Waterschoot van RAB, Lagas JS, Wagenaar E et al. Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity. Cancer Res. 69(23), 8996–9002 (2009).
  MedlineGoogle Scholar
• 59. Iusuf D, Hendrikx JJMA, van Esch A et al. Human OATP1B1, OATP1B3 and OATP1A2 can mediate the in vivo uptake and clearance of docetaxel. Int. J. Cancer 136(1), 225–233 (2015).
  Medline CASGoogle Scholar
• 60. Waterschoot van RAB, Lagas JS, Wagenaar E, Rosing H, Beijnen JH, Schinkel AH. Individual and combined roles of CYP3A, P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel. Int. J. Cancer 127, 2959–2964 (2010).
  MedlineGoogle Scholar
• 61. Cresteil T, Monsarrat B, Dubois J, Sonnier M, Alvinerie P, Gueritte F. Regioselective metabolism of toxoids by human CYP3A4 and 2C8: structure–activity relationship. Drug Metab. Dispos. 30(4), 438–445 (2002).
  Medline CASGoogle Scholar
• 62. Sofias AM, Dunne M, Storm G, Allen C. The battle of ‘nano’ paclitaxel. Adv. Drug Deliv. Rev. 122, 20–30 (2017).
  Medline CASGoogle Scholar
• 63. Joerger M, Bjermo H, Blom P, Heldring NA. Pharmacokinetics, safety and early activity of a nanoparticle micellar formulation of docetaxel in women with metastatic breast cancer: results from two randomized trials (Phase I and II). 2020 ASCO Virtual Scientific Program. J. Clin. Oncol. 38(15), 3526 (2020).
  Google Scholar
• 64. Atrafi F, van Eerden RAG, van Hylckama Vlieg MAM et al. Intratumoral comparison of nanoparticle entrapped docetaxel (CPC634) with conventional docetaxel in patients with solid tumours. Clin. Cancer Res. 26(14), 3537–3545 (2020).
  Medline CASGoogle Scholar
• 65. Deeken JF, Slack R, Weiss GJ et al. A Phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies. Cancer Chemother. Pharmacol. 71(3), 627–633 (2013).
  Medline CASGoogle Scholar
• 66. Mahalingam D, Nemunaitis JJ, Malik L et al. Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 74(6), 1241–1250 (2014).
  Medline CASGoogle Scholar
• 67. Shin BS, Kim HJ, Hong SH et al. Enhanced absorption and tissue distribution of paclitaxel following oral administration of DHP107, a novel mucoadhesive lipid dosage form. Cancer Chemother. Pharmacol. 64(1), 87–94 (2009).
  Medline CASGoogle Scholar
• 68. Ryu MH, Ryoo BY, Kim TW et al. A Phase I/IIa study of DHP107, a novel oral paclitaxel formulation, in patients with advanced solid tumors or gastric cancer. Oncologist 22(2), 129–e8 (2017).
  Medline CASGoogle Scholar
• 69. Kang YK, Ryu MH, Park SH et al. Efficacy and safety findings from DREAM: a Phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy. Ann. Oncol. 29(5), 1120–1126 (2018). •• Led to marketing authorization (in Korea) of liporaxel as first oral taxane worldwide.
  MedlineGoogle Scholar
• 70. Ahn J, Lee KS, Lee K et al. Phase 2 study of DHP107 (liporaxel, oral paclitaxel) in first-line, HER2 negative recurrent/metastatic breast cancer (OPTIMAL study, NCT03315364). Ann. Oncol. 30(Suppl. 5), v104–v142 (2019).
  Google Scholar
• 71. Kim SB, Zhang O, Sun T et al. OPTIMAL 3: a Phase III trial to evaluate the efficacy and safety of DHP107 (liporaxel, oral paclitaxel) compared to Taxol (IV paclitaxel) as first line therapy in patients with recurrent or metastatic HER2 negative breast cancer (BC) (NCT03315364). J. Clin. Oncol. 38(Suppl. 15), TPS1106 (2020).
  Google Scholar
• 72. Pluard TJ, Sharma P, Melisko ME et al. A Phase II study to evaluate the efficacy, safety and pharmacokinetics of DHP107 (liporaxal, oral paclitaxel) compared to IV paclitaxel in patients with recurrent or metastatic breast cancer: OPERA (NCT03326102). 2019 San Antonio Breast Cancer Symposium, AACR. Cancer Res. 80(Suppl. 4), Abstract OT1-0-02 (2020).
  Google Scholar
• 73. Sawicki E, Beijnen JH, Schellens JHM, Nuijen B. Pharmaceutical development of an oral tablet formulation containing a spray dried amorphous solid dispersion of docetaxel or paclitaxel. Int. J. Pharm. 511(2), 765–773 (2016).
  Medline CASGoogle Scholar
• 74. Meerum Terwogt JM, Malingré MM, Beijnen JH et al. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin. Cancer Res. 5(11), 3379–3384 (1999).
  MedlineGoogle Scholar
• 75. Malingré MM, Beijnen JH, Rosing H et al. Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Br. J. Cancer 84(1), 42–47 (2001).
  MedlineGoogle Scholar
• 76. Malingré MM, Richel DJ, Beijnen JH et al. Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J. Clin. Oncol. 19, 1160–1166 (2001).
  Medline CASGoogle Scholar
• 77. Oostendorp RL, Huitema A, Rosing H et al. Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors. Clin. Cancer Res. 15(12), 4228–4233 (2009).
  Medline CASGoogle Scholar
• 78. Ikezoe T, Hisatake Y, Takeuchi T et al. HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo. Cancer Res. 64(20), 7426–7431 (2004).
  Medline CASGoogle Scholar
• 79. Hendrikx JJMA, Lagas JS, Song JY et al. Ritonavir inhibitis intratumoral docetaxel metabolism and enhances docetaxel antitumor activity in an immunocompetent mouse breast cancer model. Int. J. Cancer 138(3), 758–769 (2016).
  Medline CASGoogle Scholar
• 80. Malingré MM, Meerum Terwogt JM, Beijnen JH et al. Phase I and pharmacokinetic study of oral paclitaxel. J. Clin. Oncol. 18(12), 2468–2475 (2000).
  Medline CASGoogle Scholar
• 81. Malingré MM, Beijnen JH, Rosing H et al. Phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A. Cancer Chemother. Pharmacol. 47(4), 347–354 (2001).
  Medline CASGoogle Scholar
• 82. Kruijtzer CM, Schellens JH, Mezger J et al. Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 20(23), 4508–4516 (2002).
  Medline CASGoogle Scholar
• 83. Kruijtzer CM, Boot H, Beijnen JH et al. Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer. Ann. Oncol. 14(2), 197–204 (2003).
  Medline CASGoogle Scholar
• 84. Helgason HH, Kruijtzer CM, Huitema AD et al. Phase II and pharmacological study of oral paclitaxel (paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer. Br. J. Cancer 95(7), 794–800 (2006).
  Medline CASGoogle Scholar
• 85. Veltkamp SA, Rosing H, Huitema AD et al. Novel paclitaxel formulations for oral application: a Phase I pharmacokinetic study in patients with solid tumours. Cancer Chemother. Pharmacol. 60(5), 635–642 (2007).
  Medline CASGoogle Scholar
• 86. Veltkamp SA, Thijsen B, Garrigue JS et al. A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer. Br. J. Cancer 95(6), 729–734 (2006).
  Medline CASGoogle Scholar
• 87. Veltkamp SA, Alderden-Los C, Sharma A, Rosing H, Beijnen JH, Schellens JH. A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application. Cancer Chemother. Pharmacol. 59(1), 43–50 (2007).
  Medline CASGoogle Scholar
• 88. Chu Z, Chen JS, Liau CT et al. Oral bioavailability of a novel paclitaxel formulation (genetaxyl) administered with cyclosporin A in cancer patients. Anticancer Drugs 19(3), 275–281 (2008).
  Medline CASGoogle Scholar
• 89. De Weger VA, Koolen SLW, Thijssen B et al. Boosting of orally administered paclitaxel by CYP3A4 inhibition. Dissertation VA de Weger, Utrecht University, ISBN: 978-94-6233-824-1, Utrecht, Chapter 2.5. 105–117 (2017).
  Google Scholar
• 90. De Weger VA, Vermunt MAC, Stuurman FE et al. A Phase I dose-escalation study of low dose metronomic treatment with oral paclitaxel, as ModraPac001 and ModraPac005, in combination with ritonavir. Clin. Pharmacol. Drug Dev. doi:10.1002/cpdd.880 (2020) (Epub ahead of print).
  Google Scholar
• 91. Lee HJ, Heo DS, Cho JY et al. A Phase I study of oral paclitaxel with a novel P-glycoprotein inhibitor, HM30181A, in patients with advanced solid cancer. Cancer Res. Treat. 46(3), 234–242 (2014).
  MedlineGoogle Scholar
• 92. Ma WW, Azad NS, Lam ET et al. A Phase I study to evaluate safety, tolerability, pharmacokinetics and activity of oraxol in patients with advanced malignancies. J. Clin. Oncol. 36(15), 2526 (2018).
  Google Scholar
• 93. Jackson CGCA, Deva S, Bayston K et al. An international randomized cross-over bio-equivalence study of oral paclitaxel ± HM30181A (oraxol) compared with weekly intravenous (IV) paclitaxel 80 mg/m² in advanced solid tumours. Ann. Oncol. 30(Suppl. 5), v159–v193 (2019).
  MedlineGoogle Scholar
• 94. Lee KW, Lee KH, Zang DY et al. Phase I/II study of weekly oraxol for the second-line treatment of patients with metastatic or recurrent gastric cancer. Oncologist 20(8), 896–897 (2015).
  Medline CASGoogle Scholar
• 95. Chen MH, Chao Y, Tenner L et al. 800P. A Phase 1b study of oraxol in combination with ramucirumab in patients with gastric or oesophageal cancers who failed previous chemotherapy. Ann. Oncol. 30(Suppl. 5), v253–v324 (2019).
  Google Scholar
• 96. Dai MS, Chao TY, Chao TC et al. Oral paclitaxel in the treatment of metastatic breast cancer (MBC) patients. J. Clin. Oncol. 37(15), 1084 (2019).
  Google Scholar
• 97. Umanzor G, Cutler DL, Barrios FJ et al. Abstract GS06-01: oral paclitaxel with encequidar: the first orally administered paclitaxel shown to be superior to IV paclitaxel on confirmed response and survival with less neuropathy: a Phase III clinical study in metastatic breast cancer. Cancer Res. 80(Suppl. 4), GS6–01 (2020). •• Demonstrated promising results for potential clinical implementation of oraxol in metastatic breast cancer.
  Google Scholar
• 98. Ravi V, Wagner M, Chen TWW et al. A Phase II study of oraxol in the treatment of unresectable cutaneous angiosarcoma. J. Clin. Oncol. 38(15), 11517 (2020). •• Updated data presented at American Society of Clinical Oncology Virtual Scientific Program 2020.
  Google Scholar
• 99. Malingré MM, Richel DJ, Beijnen JH et al. Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J. Clin. Oncol. 19, 1160–1166 (2001).
  Medline CASGoogle Scholar
• 100. Helgason HH, Koolen SLW, van Werkhoven E et al. Phase II and pharmacological study of oral docetaxel plus cyclosporin A in anthracycline pre-treated metastatic breast cancer. Curr. Clin. Pharmacol. 9(2), 139–147 (2014).
  Medline CASGoogle Scholar
• 101. De Weger VA, Koolen SLW, Moes JJ et al. Boosting of orally administered docetaxel by CYP3A4 inhibition [PhD thesis]. Utrecht University, Utrecht, The Netherlands, 39–51 (2017).
  Google Scholar
• 102. De Weger VA, Stuurman FE, Koolen SLW et al. A Phase I dose escalation study of once-weekly oral administration of docetaxel as ModraDoc001 capsules or ModraDoc006 tablet in combination with ritonavir. Clin. Cancer Res. 25(18), 5466–5474 (2019).
  MedlineGoogle Scholar
• 103. De Weger VA, Stuurman FE, Hendrikx JJMA et al. A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir. Eur. J. Cancer 86, 217–225 (2017).
  MedlineGoogle Scholar
• 104. Vermunt M, Robbrecht D, Devriese L et al. ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastasized castration-resistant prostate cancer (mCRPC): a multicenter Phase I study. ASCO 2020 Genitourinary Cancer Symposium. J. Clin. Oncol. 38(6), 79 (2020).
  Google Scholar
• 105. Vaishampayan UN, De Wit EJ, Shore ND et al. A multicenter Phase IIb trial to evaluate the efficacy and tolerability of ModraDoc006/r in subjects with metastatic castration-resistant prostate cancer (mCRPC), suitable for treatment with a taxane (NCT04028388). ASCO 2020 Genitourinary Cancer Symposium. J. Clin. Oncol. 38(6), 268 (2020). •• First clinical study with randomized comparison of oral and intravenous (IV) docetaxel in metastatic castration-resistant prostate cancer.
  Google Scholar
• 106. Vermunt MAC, Janssen JM, Vrijenhoek GL et al. Addition of an oral docetaxel treatment (ModraDoc006/r) to androgen deprivation therapy (ADT) and intensity-modulated radiation therapy (IMRT) in patients with high risk N + M0 prostate cancer. ESMO 2019 Congress. Ann. Oncol. 30(Suppl. 5), v325–v355 (2019).
  MedlineGoogle Scholar
• 107. Modra Pharmaceuticals BV. A multicenter Phase IIa study to evaluate the efficacy and tolerability of ModraDoc006/r in patients with recurrent or metastatic HER2 negative breast cancer, suitable for treatment with a taxane. https://modrapharmaceuticals.com/clinical-trials/modradoc.html
  Google Scholar
• 108. Athenex. A dose regimen-finding study to evaluate the safety, tolerability, pharmacokinetics, and activity of Oradoxel monotherapy in subjects with advanced malignancies. https://clinicaltrials.gov/ct2/show/NCT02963168
  Google Scholar
• 109. Kinex Pharmaceuticals Inc. An open-label, pilot pharmacokinetic study to determine the bioavailability, safety, and tolerability of a single dose of Oradoxel in metastatic prostate cancer patients treated with intravenous docetaxel. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=370854
  Google Scholar
• 110. Rathbun RC, Rossi DR. Low-dose ritonavir for protease inhibitor pharmacokinetic enhancement. Ann. Pharmacother. 36(4), 702–706 (2002).
  Medline CASGoogle Scholar
• 111. Brayer SW, Reddy KR. Ritonavir-boosted protease inhibitor based therapy: a new strategy in chronic hepatitis C therapy. Expert. Rev. Gastroenterol. Hepatol. 9(5), 547–558 (2015).
  Medline CASGoogle Scholar
• 112. Rogala BG, Charpentier MM, Nguyen MK, Landolf KM, Hamad L, Gaertner KM. Oral anticancer therapy: management of drug interactions. J. Oncol. Pract. 15(2), 81–90 (2019).
  MedlineGoogle Scholar
• 113. Hendrikx JJ, Lagas JS, Wagenaar E et al. Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation. Br. J. Cancer 110(11), 2669–2676 (2014).
  Medline CASGoogle Scholar
• 114. Nobili S, Landini I, Mazzei T, Mini E. Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression. Med. Res. Rev. 32(6), 1220–1262 (2012).
  Medline CASGoogle Scholar
• 115. Polizzi D, Pratesi G, Monestriroli S et al. Oral efficacy and bioavailability of a novel taxane. Clin. Cancer Res. 6(5), 2070–2074 (2000).
  Medline CASGoogle Scholar
• 116. Ramnath Hamm J, Schwartz G et al. A Phase I and pharmacokinetic study of BAY59: a novel taxane. Oncology 67(2), 123–129 (2004).
  Medline CASGoogle Scholar
• 117. Silvani A, De Simone I, Fregoni V et al. Multicenter, single arm, Phase II trial on the efficacy of ortataxel in recurrent glioblastoma. J. Neurooncol. 142(3), 455–462 (2019).
  Medline CASGoogle Scholar
• 118. Beer M, Lenaz L, Amadori D et al. Phase II study of ortataxel in taxane-resistant breast cancer. J. Clin. Oncol. 26(15), 1066–1066 (2008).
  MedlineGoogle Scholar
• 119. Mastalerz H, Cook D, Fairchild GR et al. The discovery of BMS-275183: an orally efficacious novel taxane. Bioorg. Med. Chem. 11(20), 4315–4323 (2003).
  Medline CASGoogle Scholar
• 120. Bröker LE, De Vos FYFL, van Groeningen CJ et al. Phase I trial with BMS-275183, a novel oral taxane with promising antitumor activity. Clin. Cancer Res. 12(6), 1760–1767 (2006).
  MedlineGoogle Scholar
• 121. Bröker LE, Valdivieso M, Pilat MJ et al. Effect of food on the pharmacokinetic behavior of the potent oral taxane BMS-275183. Clin. Cancer Res. 14(13), 4186–4191 (2008).
  MedlineGoogle Scholar
• 122. Bröker LE, Veltkamp SA, Heath EI et al. A Phase I safety and pharmacological study of a twice weekly dosing regimen of the oral taxane BMS-275183. Clin. Cancer Res. 13(13), 3906–3912 (2007).
  MedlineGoogle Scholar
• 123. Heath EI, Lorusso P, Ramlingam SS et al. A Phase I study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies. Invest. New Drugs 29(6), 1426–1431 (2011).
  Medline CASGoogle Scholar
• 124. Bristol-Myers Squibb Company. Final clinical study report for study CA165020. A randomized, two-cohort Phase II study of two doses of BMS-275183 given on a weekly schedule in patients with pre-treated non-small cell lung cancer. www.clinicaltrialsregister.eu/ctr-search/trial/2004-000119-24/results
  Google Scholar
• 125. Sampath D, Discafani CM, Loganzo F et al. MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo. Mol. Cancer Ther. 2(9), 873–884 (2003).
  Medline CASGoogle Scholar
• 126. Lockhart AC, Bukowski R, Rothenberg ML et al. Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumours. Cancer Chemother. Pharmacol. 60(2), 203–209 (2007).
  Medline CASGoogle Scholar
• 127. Ramanathan RK, Picus J, Raftopoulos H et al. A Phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer. Cancer Chemother. Pharmacol. 61(3), 453–458 (2008).
  Medline CASGoogle Scholar
• 128. Mekhail T, Serwatowski P, Dudek A et al. A Phase II study of intravenous (IV) milataxel (M) for the treatment of non-small cell lung cancer (NSCLC) refractory to platinum-based therapy. J. Clin. Oncol. 24(18), 7098–7098 (2006).
  Google Scholar
• 129. Syed SK, Beeram M, Takimoto CH et al. Phase I and pharmacokinetics (PK) of DJ-927, an oral taxane, in patients (Pts) with advanced cancers. J. Clin. Oncol. 22(14), 2028–2028 (2004).
  Google Scholar
• 130. Lang A, Beeram M, Tolcher AW et al. Phase I development of a weekly dosing schedule for the oral taxane tesetaxel. J. Clin. Oncol. 30(15), 2555 (2012).
  Google Scholar
• 131. Saif MW, Sarantopoulos J, Patnaik A, Tolcher AW, Takimoto C, Beeram M. Tesetaxel, a new oral taxane, in combination with capecitabine: a Phase I, dose-escalation study in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 68(6), 1565–1573 (2011).
  Medline CASGoogle Scholar
• 132. Mulcahy MF, Baker JS, Sun W et al. Phase 2 trial of tesetaxel, an oral taxane, as 2nd-line therapy for patients with advanced gastro-oesophageal cancer. J. Clin. Oncol. 30(15), 4077 (2012).
  MedlineGoogle Scholar
• 133. Baas P, Szczęsna A, Albert I et al. Phase I/II study of a 3 weekly oral taxane (DJ-927) in patients with recurrent, advanced non-small cell lung cancer. J. Thorac. Oncol. 3(7), 745–750 (2008).
  MedlineGoogle Scholar
• 134. Seidman AD, Schwartzberg LS, Gudena VK et al. Activity of tesetaxel, an oral taxane, given as a single-agent in patients (Pts) with HER2-, hormone receptor ± (HR+) locally advanced or metastatic breast cancer (MBC) in a Phase 2 study. J. Clin. Oncol. 36(15), 1042 (2018).
  Google Scholar
• 135. O'Shaughnessy J, Piccart M, Schwartzberg LS et al. CONTESSA: a multinational, multicenter, randomized, Phase III registration study of tesetaxel plus a reduced dose of capecitabine in patients (pts) with HER2-, hormone receptor ± (HR+) locally advanced or metastatic breast cancer (LA/MBC) who have previously received a taxane. J. Clin. Oncol. 37(15), 1107 (2019). •• Randomized clinical Phase III study investigating an all oral regime with tesetaxel/capecitabine in metastatic breast cancer.
  Google Scholar
• 136. Tolaney SM, Bondarenko I, Chan A et al. CONTESSA TRIO: a multinational, multicenter, Phase (P) II study of tesetaxel (T) plus three different PD-(L)1 inhibitors in patients (Pts) with metastatic triple-negative breast cancer (TNBC) and tesetaxel monotherapy in elderly pts with HER2-metastatic breast cancer (MBC). J. Clin. Oncol. 38(15), 1111 (2020).
  Google Scholar
• 137. Skwarczynski M, Hayashi Y, Kiso Y. Paclitaxel prodrugs: toward smarter delivery of anticancer agents. J. Med. Chem. 49(25), 7253–7269 (2006).
  Medline CASGoogle Scholar
• 138. Bedikian AY, DeConti RC, Conry R et al. Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma. Ann. Oncol. 22(4), 787–793 (2011).
  Medline CASGoogle Scholar
• 139. Paz-Ares L, Ross H, O'Brien M et al. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br. J. Cancer 98(10), 1608–1613 (2008).
  Medline CASGoogle Scholar
• 140. O'Brien ME, Socinski MA, Popovich AY et al. Randomized Phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer. J. Thorac. Oncol. 3(7), 728–734 (2008).
  MedlineGoogle Scholar
• 141. Kang JAE, Sin JH, Lee HL et al. Inhibition of pancreatic cancer cell viability and tumor growth through cell cycle arrest by an oral formulation of docetaxel. Int. J. Pharmacol. 15, 994–1000 (2019).
  CASGoogle Scholar
• 142. Ren T, Wang Q, Xu Y et al. Enhanced oral absorption and anticancer efficacy of cabazitaxel by overcoming intestinal mucus and epithelium barriers using surface polyethylene oxide (PEO) decorated positively charged polymer-lipid hybrid nanoparticles. J. Control. Release 269, 423–438 (2018).
  Medline CASGoogle Scholar
• 143. Tang SC, Kort A, Cheung KL et al. P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain disposition and oral availability of the novel taxane cabazitaxel (Jevtana) in mice. Mol. Pharm. 12(10), 3714–3723 (2015).
  Medline CASGoogle Scholar